Karachi: BF Biosciences Limited, a prominent biotech firm, recently concluded its initial public offering (IPO), capturing significant investor attention with a robust response. According to data confirmed on October 9, 2024, the public subscription figures indicated a substantial commitment from investors, as detailed in a report submitted to the Pakistan Stock Exchange.

The IPO, conducted on October 2 and 3, 2024, offered a total of 6.325 million shares. According to information available from the Pakistan Stock Exchange (PSX), the offering was met with enthusiasm, totaling 487.025 million PKR in capital raised through various subscription categories. The smallest subscription tier for 500 shares attracted 1,520 applications, accounting for 760,000 shares, translating to 58.52 million PKR. The largest interest was seen in the category for subscriptions above 2,000 shares, which drew 238 applications and secured 4.3 million shares, amounting to 331.06 million PKR.

Applications for up to 2,000 shares received full allotment, showcasing the robust demand across investor classes, while those applying for more than 2,000 shares were allotted shares on a pro-rata basis. This tiered approach allowed for a broad base of investor participation, indicating strong market confidence in BF Biosciences' future prospects.

This successful capital raising event highlights the growing investor confidence in Pakistan's biotech sector and marks a significant milestone for BF Biosciences as it aims to expand its research and development capabilities.